Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2020-01-13

Clinical Trial Update: Enzalutamide for Patients With Androgen Receptor Positive Salivary Cancers [Phase 2]

View source ↗

Summary

Phase 2 trial results of enzalutamide in patients with androgen receptor–positive salivary gland cancer have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Enzalutamide (enzalutamide)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Salivary Cancer | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2020-01-13